TED-A9 (A9-DPC) vs UX-DA001

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopaminergic neuron replacement · full Parkinson's Disease pipeline

TED-A9 (A9-DPC)

Developed by S.Biomedics

Phase 1/2 in Parkinson's Diseasecell therapy
Weak signal

NCT05887466 · Phase 1/2 · completed

The study assigned six participants to each of two dose groups without randomization, blinding, or a placebo or active comparator. Its primary outcomes focused on adverse events and transplant failure or rejection. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2029 · NCT06477744 (registry estimate)

Reported efficacy

Occurrence of treatment-emergent adverse events (TEAEs) after administration of the IP (Up to 96 Weeks (24 months) after IP administration); Failure or rejection of transplantation (Week 12 (3 months)); Failure or rejection of transplantation (Week 24 (6 months)); Failure or rejection of transplantation (Week 48 (12 months)); Failure or rejection of transplantation (Week 96 (24 months)); Occurrence of bleeding (Week 12 (3 months)); Occurrence of bleeding (Week 24 (6 months)); Occurrence of bleeding (Week 48 (12 months)); Occurrence of bleeding (Week 96 (24 months)); Occurrence of infection (Week 12 (3 months)); Occurrence of infection (Week 24 (6 months)); Occurrence of infection (Week 48 (12 months)); Occurrence of infection (Week 96 (24 months)); Occurrence of adverse event of special interest (AESI)* after administration of the IP (Up to 96 Weeks (24 months) after IP administration): Primary endpoint (occurrence of TEAEs) at the 12-month interim readout: 1 of 12 participants had a mild hemorrhage unrelated to the transplant site; no cell/graft-related adverse events or other neurological abnormalities/side effects reported.

Result source: NCT05887466

UX-DA001

Developed by Shanghai UniXell Biotechnology Co., Ltd

Phase 1 in Parkinson's Diseasecell therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06778265 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTED-A9 (A9-DPC)UX-DA001
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

TED-A9 (A9-DPC)
—Not reported
UX-DA001
—Not reported

ON time without troublesome dyskinesia, change

TED-A9 (A9-DPC)
—Not reported
UX-DA001
—Not reported

UPDRS Part III, change

TED-A9 (A9-DPC)
—Not reported
UX-DA001
—Not reported

MDS-UPDRS Part II, change

TED-A9 (A9-DPC)
—Not reported
UX-DA001
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TED-A9 (A9-DPC): no structured comparison results are available for Parkinson's Disease.

UX-DA001: no structured comparison results are available for Parkinson's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TED-A9 (A9-DPC)'s landscape · UX-DA001's landscape